Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 1, 2011

U.S. Army Awards $45.5M Contract to PPD for Clinical Trial Management

  • PPD will provide global regulatory and biostatistical services for a range of clinical development programs funded by the U.S. Army under a five-year, $45.5 million contract. The goal is to ensure regulatory compliance for Army clinical programs as well as support biodefense, biopreparedness, and vaccine development initiatives to protect military personnel.

    The company will help the Army prepare and file clinical trial submissions to FDA and other regulatory authorities worldwide. Also, PPD biostatisticians will provide statistical consulting, study design support, and statistical analysis.

    PPD says has delivered clinical support services to global U.S. Government R&D programs for 21 years. It adds that it has collaborated on more than 900 government and public health drug development projects including programs on infectious diseases, vaccines, biodefense, autoimmune diseases, and asthma/allergic diseases.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »